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Urinary and reproductive tracts not only have common
embriologic origin but also are linked anatomically
and functionally. Both systems require ovarian sex
steroids for proper function. The occurrence of surgi-
cal or natural menopause is associated with sharp
increase of urogenital tract disturbances including
stress urinary incontinence, overactive bladder syn-
drome, recurrent urinary tract infections, pelvic organ
prolapse and vaginal atrophy. 
On the one hand, sex steroids are widely believed
to be useful in the treatment of above mentioned ail-
ments. On the other hand, there is scarcity of high
quality data proving the efficacy of sex hormones in
these clinical settings. The background for the admin-
istration of the hormone replacement therapy (HRT) in
the urogynecology is the identification of both type α
and type β estrogen receptors (ER) and progesterone
receptors in the pelvic floor support structures, vagina,
urethra, trigone and central nervous systems neurons
controlling micturition reflexes (Table 1). 
The influence of sex hormones on lower
urinary tract function
Cyclic fluctuations of sex steroids levels affect lower
urinary tract function. Urodynamic data showed 6%
increase of functional length of urethra in periovulato-
ry when compared to postmenstrual phase [1]. The
instability of detrusor is markedly increased in late
secretory phase. This phenomenon may be explained
by the procontractory effect of progestrone that is able
to antagonise estrogen-dependent relaxation of the
detrusor [2].
Abnormal function of hypothalamus-pituitary-
ovarian axis is linked to the deficiency of continence
mechanism in reproductive age women. Also, dysuric
symptoms are attributed to hypoestrogenism, anorexia
and polycystic ovarian syndrome [3,4].
Epidemiological data clearly show that rapid
increase of all urogynecological disturbances parallels
with the occurrence of  menopause. The value of max-
imal urethral closure pressure - the main urodynamic
parameter reflecting function of continence mecha-
nism is markedly decreased in the menopausal women.
Also, bladder capacity and detrusor pressure during
micturition are significantly lowered in elderly popula-
tion. Urinary incontinence became common condition
affecting from 19 to even 70% of investigated subjects
[5]. In some analyses nearly half of menopausal
women suffer from stress urinary incontinence, while
another 20% report urge incontinence [6]. 
Urogenital atrophy related to the 
hypoestrogenism
Nearly 75% of women in late menopause experience
genital disturbances related to hypoestrogenism (Table
2). Most bothersome are vaginal dryness, thinning of
mucosa and loss of elasticity of vaginal wall, atrophy
of uterine cervix, atrophy of the vulva and clitoris,
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decrease of pelvic floor muscle tone. Epithelium of
vaginal portion of uterine cervix became thin and
prone to injury [7].
Hypoestrogenism induced changes of vaginal flora
composition increase the risk of lower urinary tract
infections. Profound mucosal atrophy leads to dyspau-
renia that is even made worse by itching and burning
of the vulva. Sexually inactive menopausal women
experience contraction and gradual obliteration of the
vagina. 
Consequences of the chronic hypoestrogenism
for the lower urinary tract
Menopausal urinary symptoms - improper perception
of bladder fullness, dysuria, polyuria, nocturia, overac-
tive bladder syndrome and stress or mixed urinary
incontinence at least in part may be linked to the atro-
phy of trigone, loss of pelvic floor striated muscle
tone, improper collagen metabolism leading to the ure-
thral stiffness and finally, the decrease of the activity
of α-adrenergic system [8]. Moreover, thinning of ure-
thral mucosa and decrease of urethral blood flow
reduce intraurethral pressure and lead to the develop-
ment of stress urinary incontinence [9] (Table 3). 
The influence of estrogens on the pelvic floor
connective tissue metabolism
Most data on estrogen regulation of connective tissue
metabolism came from animal models. Unfortunatelly
human studies are scarce and their results inconclu-
sive. The influence of estrogens on connective tissue
may be dependent on the regulation of collagen metab-
olism (Table 4). Estrogens not only stimulate biosyn-
tehesis of the fibrillar collagens but also increase syn-
thesis, secretion and activity of metalloproteinases.
These enzymes are able to degrade numerous connec-
tive tissue components including collagens and play
crucial role in connective tissue remodelling during
wound healing. 
Studies on women with stress urinary incontinence
showed diminished fibrillar collagen content in skin,
vaginal epithelium stroma, pubocervical fascia and
round ligaments [10-12]. Estrogen replacement thera-
py (ERT) increase skin total collagen content by 48%
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Table 1. The distribution of the sex steroids receptors within uro-
genital diaphragm. 
Table 2. The effects of estrogen deprivation on vagina, pelvic floor
and vulva.
when compared to control menopausal women. Also
the rate of skin collagen loss is lower in women on
ERT [13]. Jackson et al. [11] showed that ERT induce
metabolism of vaginal connective tissue only after 6-
month use. Simultaneously, the total collagen content
decrease mainly due to induction of activity of col-
lagenolytic enzymes. The author concluded that possi-
bly long term ERT is able to increase collagen content
in the vaginal wall. 
The clinical value of estrogen administration
in urogynecology
Profound decrease in estrogen concentration associat-
ed with menopause has been considered as a factor
responsible for the increasing urinary incontinence
prevalence in aging  women. As it was mentioned
before estrogens have been shown to influence in pos-
itive way several parameters responsible for proper
functioning of female continence mechanism such as
increase in urethral closure pressure [14], increase in
urethral blood flow [15], increase of α-adrenergic
receptor sensitivity [16], restoration of cellular lining
of both the vagina and urethra [17].
Data from these experimental studies and clinical
observations from few nonrandomized trials caused
inclusion of both systemic and vaginal estrogens to
medical management of urinary incontinence in post-
menopausal women. This attitude was further support-
ed by the results of review that showed subjective
improvement (64-75%) of SUI symptoms after estro-
gen administration [14]. In 2003 Moehrer et al. [18]
published study based on Cochrane database compiled
from twenty eight trials which included 2926 women.
Analyzed trials used varying types of estrogen, dose,
duration of treatment and length of follow-up. Sample
sizes ranged from 16 to 1525 subjects. In the 15 trials
that compared estrogen with placebo, 374 women
received estrogen and 344 placebo. Subjective impres-
sion of cure was higher amongst those treated with
estrogen for all categories of incontinence (36/101,
36% versus 20/96, 21%; RR for cure 1.61, 95% CI:
1.04 to 2.49). When subjective cure and improvement
were considered together, higher cure and improve-
ment rates were shown for both urge (35/61, 57% ver-
sus 16/58, 28% on placebo) and stress (46/107, 43%
versus 29/109, 27%) incontinence. For women with
urge incontinence, the chance of cure or improvement
was approximately a quarter higher than in women
with stress incontinence. Taking all trials together, the
data suggested that about 50% of women treated with
estrogen were cured or improved compared with about
25% on placebo. The final conclusion was that estro-
gen treatment can improve or cure incontinence and
the evidence suggests that this is more likely with urge
incontinence. However, the combined estrogen and
progesterone appeared to reduce the likelihood of cure
or improvement. Because of lack of data authors were
not able to address reliably other aspects of estrogen
therapy such as estrogen type, dose and route of
administration. Finally authors of this review stated
that the risk of endometrial and breast cancer after
long-term use suggests that estrogen administration in
order to treat incontinence should be used for limited
periods, especially in women with an intact uterus.
Moreover, Osamu et al. [19] clearly demonstrated that
there are significant interactions between estrogen and
the female lower urinary tract because the combination
of estriol (E3) and pelvic floor muscle exercises
(PFME) was significantly more effective three months
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Table 3. The influence of estrogens on the function of urinary
bladder and urethra.
Table 4. The influence of estrogens on collagen metabolism
after the commencement of therapy than was PFME
alone. The effect of E3 persisted for as long as 18
months in the mild urinary incontinence groups. The
finding that the combined effect of E3 could be detect-
ed for up to 12 months is important because it indicates
the need to use estrogen with PFME for at least one
year in stress incontinence. 
On the other hand data from the randomized, dou-
ble-blinded, placebo-controlled trials clearly show that
estrogen should not be used in the prevention or relief
of stress and urge incontinence. Indeed, in both the
Heart Estrogen and Progestin Replacement Study
(HERS) [20] and Women's Health Initiative (WHI)
authors demonstrated a statistically significant
increase of the risk of developing incontinence or a
worsening of incontinence after the initiation of estro-
gen [21]. Among the 1 525 women who reported in-
continence at baseline, daily intake of 0.625 mg conju-
gated estrogen (CEE) and 2.5 mg of medoxyproges-
terone acetate (MPA) caused worsening in urinary
incontinence episodes (the odds ratio for worsening
incontinence was 1.5 among women who reported
incontinence at the baseline). In a follow-up study of
women in HERS who were continent at baseline, the
odds ratio for developing new stress incontinence was
1.7 and urge incontinence was 1.5. Four years of treat-
ment with hormone therapy caused an excess risk of
12% for weekly urge incontinence and 16% for week-
ly stress incontinence [22]. Clinical messages from the
WHI study were similar. After 1 year, standard doses
of estrogen (0.625 mg) with or without MPA increased
the incidence of symptoms of stress and urge inconti-
nence. The risk was greatest for stress incontinence
(odds ratio for CEE-MPA was 1.8 and for CEE alone
was 2.2). CEE-MPA had no significant effect on the
development of urge incontinence but CEE alone
increased the odds of new urge incontinence by 1.3.
Women who reported incontinence at the start of the
study had a 1.4 odds of worsening incontinence on
CEE-MPA and 1.5 on CEE alone compared to placebo,
however there was no significant increase in urinary
incontinence in women aged <60 years [21]. More-
over, 12 clinical trials analyzed recently by Waetjen
and Dwyer revealed that estrogen given to post-
menopausal women had either negative or neutral
effect on urinary incontinence symptoms [23]. It is
unclear why the results of hormone therapy in terms of
various types of female UI are so different and even
conflicting. Alpha and beta estrogen receptors have
been identified throughout the urogenital tract, includ-
ing the bladder mucosa, trigone, urethra, and vaginal
mucosa [24].
These receptors were also identified in almost all
structures responsible for proper support of the pelvic
organs [25,26]. This is an indirect evidence that estro-
gen may have an important role in proper functioning
of female urinary continence mechanism. Taking this
into account it was surprising that in number of studies
administration of estrogen resulted in a reduction of
the total collagen concentration, a decrease in the
cross-linking of collagen, and an increase in markers
of collagen turnover in the periurethral tissues of
incontinent women [27,28]. However, we have to
remember that the balance of the two types of ER may
change during transition from pre- to post-menopause,
with ER-α predominating over ER-β in older group
[29]. Moreover, ER-α density varies with estrogen use
while ER-β does not, and this finding is of critical
importance since ER-β is a dominating type of ER in
urogenital tract before menopause, while in late
menopause only α subtype is present [30]. Since in
HERS study the average age of patients treated was 66
years and also 2/3 of the women from WHI were in late
menopause it is not surprising that estrogen could sim-
ply not act properly on urogenital tract since the lack of
ER-beta which is present in premenopausal women.
In animal studies estrogen administration changed
the ratio of collagen to smooth muscle fibers and this
was associated with higher bladder contractility and
resting tension [31,32]. Other changes seen with estro-
gen treatment include increased peri-urethral vascular-
ity. In rats and monkeys, estrogen increased the loose,
vascular connective tissue component of the urethra,
which could increase the coaptation of urethral wall
[33,34]. Finally, estrogen has a neuromodulation func-
tion, increasing sympathetic nerve density (which
physiologically promote urine storage) in the pelvis
and regulating neurotrophins but how this  may affect
continence is unknown [35].
To summarize, it seems that estrogen is not effec-
tive and could actually be detrimental in women
already presenting symptoms of stress urinary inconti-
nence whereas it appears that estrogen is beneficial for
postmenopausal women with urgency and urge urinary
incontinence [36,37]. Taking into account messages
from the WHI study which found not significant
increase in urinary incontinence in women aged <60
years while on hormone treatment it is reasonable to
speculate that starting estrogen replacement soon after
the menopause may be effective in preventing, or at
least delaying the onset of stress incontinence.
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